Comparing the Prognosis of Patients With Cardia and Non-cardia Gastric Cancer.

Gastric Cancer Clinical Trial

Official title:

Comparing the Stage-for-Stage Prognosis of Patients With Cardia and Non-cardia Gastric Cancer After Operation.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03895008
• Other study ID #: AHQU-2019001
• Status: Recruiting
• Start date: July 8, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: March 2019
• Source: Affiliated Hospital of Qinghai University
• Contact: Jiuda Zhao, M.D.
• Phone: +869716162732
• Email: jiudazhao[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To comparing the stage-for-stage prognosis of patients with cardia and non-cardia gastric cancer after operation.

Description:

The aim of this study is to compare the stage-for-stage prognosis of patients with cardia and non-cardia gastric cancer after operation.In this study, patients with cardiac and non-cardiac gastric cancer who undergo radical resection from January 2019 to December 2024 will be included. We will follow up the patient's progression, recurrence time and survival time.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Histopathology or cytopathology proven cardia or non-cardia gastric cancer;

2. Operable gastric cancer patients: primary lesions can be completely excision, no distant metastasis;

3. Life expectancy of at least 6 months;

4. ECOG(Eastern Cooperative Oncology Group ) score 0-1;

5. Age: 18~80 years old;

6. Normal hemodynamic indices before the recruitment (including blood cell count and liver/kidney function).

For example: WBC(White blood cell count )>4.0×109/L; NEU(Neutrophils)>1.5×109/L; PLT(Platelet)>100×109/L;

7. Roughly normal cardiopulmonary function: No coronary heart disease, myocardial infarction, pulmonary heart disease, refractory hypertension;

8. Not concomitant with other uncontrollable benign diseases before the recruitment;

9. Voluntarily signed the informed consent.

Exclusion Criteria:

1. Advanced gastric cancer patients with distant metastasis and inoperable ;

2. Pregnant or lactating women;

3. Patients who have no desire to participate in the study.

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Other:
• Cardia and Non-cardia gastric cancer
We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.

Locations

Country	Name	City	State
China	The Second Hospital of Lanzhou University	Lanzhou	Gansu
China	Affiliated Hospital of Qinghai University	Xining	Qinghai
China	People's Hospital of Qinghai Province	Xining	Qinghai

Sponsors (3)

Lead Sponsor	Collaborator
Affiliated Hospital of Qinghai University	LanZhou University, Qinghai People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Free Survival(DFS)	The time from the primary operation to disease recurrence or death.	5 years
Secondary	Overall survival(OS)	OS is defined as the time from the end of radical surgery to death for any reason or at the last follow-up.	5 years